Skip to content
DataLookout
Menu

NCT07911995

A Trial to Investigate the Efficacy and Safety of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date pushed from Nov 9, 2026 to Nov 30, 2026
    • Secondary endpoints: 17 to 4
    • Study title shortened, about 5 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Core Phase: Change From Baseline in Time-to-Stand-from-Supine (TTSTAND) Velocity
Timeframe: Baseline to Week 24
Extension Phase: Incidence of Adverse Events
Timeframe: First dose through Week 96

Secondary (4)

Core Phase: Change From Baseline in Stride Velocity 95th Centile (SV95C)
Core Phase: Change From Baseline in 10-Meter Walk/Run (10MWR) velocity
Core Phase: Change From Baseline in Time-to-Climb-4-Stairs (TTCLIMB) velocity
Core Phase: Incidence of Adverse Events

Arms and interventions

Tegacorat Low doseExperimental

Tegacorat Treatment Group 1

Tegacorat Mid DoseExperimental

Tegacorat Treatment Group 2

Tegacorat High doseExperimental

Tegacorat Treatment Group 3

Drugs: Tegacorat